All In Biotech

Drug Trial Radar · NCT01093326

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

May 12, 2010

Primary completion

Sep 6, 2023

Study completion Sep 6, 2023

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Conditions

  • Multiple Sclerosis

Interventions

  • Ponesimod 10 mgDrug

    Ponesimod 10 mg oral use

  • Ponesimod 20 mgDrug

    Ponesimod 20 mg oral use

  • Ponesimod 40 mgDrug

    Ponesimod 40 mg oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR) of Confirmed RelapsesTime frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
  2. Time to First Confirmed RelapseTime frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
  3. Time to 24 Weeks Confirmed Disability ProgressionTime frame: From ponesimod baseline up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years

Locations

71 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Palo Alto, California

  • Site not named

    Sacramento, California

  • Site not named

    Venice, Florida

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Kansas City, Kansas

  • Site not named

    Lenexa, Kansas

  • Site not named

    Latham, New York

  • Site not named

    Schenectady, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Burlington, Vermont

  • Site not named

    Kirkland, Washington

  • Site not named

    Vienna, Austria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Brno, Czechia

  • Site not named

    Jihlava, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Ostrava-Poruba, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Teplice, Czechia

  • Site not named

    Helsinki, Finland

  • Site not named

    Hyvinkää, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Montpellier, France

  • Site not named

    Berlin, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Ulm, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Esztergom, Hungary

  • Site not named

    Győr, Hungary

  • Site not named

    Miskolc, Hungary

  • Site not named

    Tel HaShomer, Israel

  • Site not named

    Tsrifin, Israel

  • Site not named

    Breda, Netherlands

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.